The economics of personalized medicine: A model of incentives for value creation and capture

Drug Information Journal

Volumn 41, Issue 4, 2007, Pages 501-509

  Garrison Jr , Louis P ^a   Austin, M J Finley ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

Economics of diagnostics; Linked diagnostic therapeutics; Personalized medicine; Value based reimbursement

Indexed keywords

ARTICLE; CONCEPTUAL FRAMEWORK; COST; DIAGNOSTIC TEST; DRUG MARKETING; GENOMICS; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH ECONOMICS; HUMAN; MEDICINE; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 34447255634     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100408     Document Type: Article

References (16)

1. Robertson JA, Brody B, Buchanan A, et al. Pharmacogenetic challenges for the health care system. Health Aff. 2002;21:155-167.
2. Webster A, Martin P, Lewis G, Smart A. Integrating pharmacogenetics into society: in search of a model. Nature Rev Genet. 2004;5: 663-668.
3. Califf RM. Defining the balance of risk and benefit in the era of genomics and proteonomics. Health Aff. 2004;23:77-87.
4. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004;5:1139-1149.
5. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci. 2000;2: article 29.
6. Flowers CR, Veenstra D. Will pharmacogenomics in oncology be cost-effective? Oncol Econ. 2000;1:26-33.
7. Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics. 2004;22:481-493.
8. Bala MV, Zarkin GA. Pharmacogenomics and the evolution of healthcare: is it time for cost-effectiveness analysis at the individual level? Pharmacoeconomics. 2004;22:495-498.
9. Danzon P, Towse A. The economics of gene therapy and of pharmacogenetics. Value Health. 2002;5:5-13.
10. Raab GG, Logue LJ. Medicare coverage of new clinical diagnostic tests: the need for coding and payment reform. Clin Leadership Manage Rev. November-December 2001:376-387.
11. Towse A. The efficient use of pharmaceuticals: does Europe have any lessons for a Medicare drug benefit? Health Aff. 2003;22:42-45.
12. Hall S. Personalized Medicine's bitter pill. February 2003. Available at: http://www.technologyre view.com/Therapeutics/wtr_13062,259,p1.html. Accessed February 26, 2006.
13. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
14. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005; 352:2285-2293.
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-2139.
16. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol. 2005;23:6838-6845.